Delivery of drugs by the pulmonary route

Modern Pharmaceutics: Fifth Edition

Volumn 2-2, Issue , 2016, Pages 191-219

  Hickey, Anthony J ^a   Mansour, Heidi M ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942315255     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Sciarra JJ. Pharmaceutical aerosols. In: Lachman L, Lieberman HA, Kanig JL, eds. The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea and Febiger, 1970:605-638.
2. Thiel CG. From Susie's Question to CFC Free: An Inventor's Perspective on Forty Years of MDI Development and Regulation. Respiratory Drug Delivery V. Phoenix, AZ: Davis Healthcare International Publishing, LLC, 1996:115-123.
3. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom catalyzed destruction of ozone. Nature 1974; 249:1810.
4. Montreal Protocol 1987. Montreal protocol on substances that deplete the ozone layers, 1987.
5. Hickey AJ, Dunbar CA. A new millenium for inhaler technology. Pharm Technol 1997; 21:116-125.
6. Gonda I. Targeting by deposition. In: Hickey AJ, ed. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, Inc., 1992:61-82.
7. Allen T. Particle Size Measurement. 4th ed. London: Chapman and Hall, 1993.
8. Raabe OG. Aerosol aerodynamic size conventions for inertial sampler calibration. J Air Pollut Control Assoc 1976; 26:856-860.
9. Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. 2nd ed. New York: John Wiley and Sons, Inc, 1999.
10. Ferron GA, Oberdorster G, Henneberg R. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth. J Aerosol Med 1989; 2:271-283.
11. Hickey AJ, Martonen TB. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm Res 1993; 10:1-7.
12. Weibel ER. Morphometry of the Human Lung. Berlin: Springer Verlag, 1963.
13. Horsfield K, Woldenberg MJ. Branching ratio and growth of tree-like structures. Respir Physiol 1986; 63:97-107.
14. Findeisen W. Über das Absetzen kleiner, in der Luft suspendierten Teilchen in der menschlichen Lunge bei der Atmung. Arch Ges Physiol 1935; 236:367.
15. Martonen TB, Katz I, Fults K, et al. Üse of analytically defined estimates of aerosol respirable fraction to predict lung deposition patterns. Pharm Res 1992; 9:1634-1639.
16. Hatch TF, Gross P. Physical Factors in Respiratory Deposition of Aerosols. Pulmonary Deposition and Retention of Inhaled Aerosols. New York: Academic Press, 1964:27-43.
17. Chaffee VW. Surgery of laboratory animals. In: Melby EC, Altman NH, eds. Handbook of Laboratory Animal Science. Cleveland: CRC Press, Inc., 1974:233-273.
18. Phalen RF, Oldham MJ. Tracheobronchial airway structure as revealed by casting techniques. Am Rev Respir Dis 1983; 128:S1-S4.
19. Landahl HD. On the removal of air-borne droplets by the human respiratory tract. I. The Lung. Bull Math Biophys 1950; 12:43.
20. ICRP P. Human respiratory tract model for radiological protection. Ann ICRP 1994; 24:1-3.
21. McCusker K, Hiller FC, Wilson JD, et al. Aerodynamic sizing of tobacco smoke particulate from commercial cigarettes. Arch Environ Health 1983; 38:215-218.
22. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 1983; 125:S59-S65.
23. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75:433-438.
24. Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J Pharm Sci 1988; 77:340-348.
25. Hochhaus G, Suarez S, Gonzalez-Rothi RJ, et al. Pulmonary Targeting of Inhaled Glucocorticoids: How Is it Influenced by Formulation. Respiratory Drug Delivery VI. Hilton Head, SC: Interpharm Press, Inc., 1998:45-52.
26. Hickey AJ. Lung deposition and clearance of pharmaceutical aerosols: what can be learned from inhalation toxicology and industrial hygiene? Aerosol Sci Technol 1993; 18:290-304.
27. Hickey AJ, Mansour HM. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. In: Rathbone MJ, Hadgraft J, Roberts MS, et al. (eds.), Modified-Release Drug Delivery Technology, Vol 2, Drugs and the Pharmaceutical Sciences Series, 2nd ed. New York: Informa Healthcare, 2008: 573-602.
28. Dunbar C, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Part 1998; 16:7-45.
29. Chow AHL, Tong HHY, Chattopadhyay P, et al. Particle engineering for pulmonary drug delivery. Pharm Res 2007; 24:411-437.
30. Mosen K, Backstrom K, Thalberg K, et al. Particle formation and capture during spray-drying of inhalable particles. Pharm Dev Technol 2004; 9:409-417.
31. Vidgren MT, Vidgren PA, Paronen TP. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. Int J Pharm 1987; 35:139-144.
32. Van Oort MM, Sacchetti M. Spray-drying and supercritical fluid particle generation techniques. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. 2nd ed. New York: Informa Healthcare, 2007:307-346.
33. Tong HHY, Chow AHL. Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing. KONA Powder Part 2006; 24:27-40.
34. Tom JW, Debendetti PG. Particle formation with supercritical fluids-a review. J Aerosol Sci 1991; 22:555-584.
35. York P, Kompella ÜB, Shekunov BY. Supercritical Fluid Technology for Drug Product Development. 1st ed. New York: CRC Press, 2004.
36. Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci 2004; 22:1-17.
37. Shekunov BY. Production of powders for respiratory drug delivery. In: York P, Kompella UB, Shekunov BY, eds. Supercritical Fluid Technology for Drug Product Development. New York: Marcel Dekkar, 2004:247-282.
38. Shekunov BY, Chattopadhyay P, Seitzinger J, et al. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 2006; 23:196-204.
39. Shekunov BY, Feeley JC, Chow AHL, et al. Physical properties of supercritically-processed and micronised powders for respiratory drug delivery. KONA Powder Part 2002; 20:178-187.
40. Shekunov BY, Feeley JC, Chow AHL, et al. Aerosolisation behaviour of micronised and supercritically processed powders. J Aerosol Sci 2003; 34:553-568.
41. Schiavone H, Palakodaty S, Clark A, et al. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 2004; 281:55-66.
42. Velaga SP, Bergh S, Carlfors J. Stability and aerodynamic behaviour of glucocorticoid particles prepared by a supercritical fluids process. Eur J Pharm Sci 2004; 21:501-509.
43. Lobo JM, Schiavone H, Palakodaty S, et al. SCF-engineered powders for delivery of budesonide from passive DPI devices. J Pharm Sci 2005; 94:2276-2288.
44. Dalby RN. Halohydrocarbons, pharmaceutical usesIn: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, Inc., 1993:161-180.
45. Atkins P. Physical Chemistry. 5th ed. New York: W.H. Freeman and Company, 1994.
46. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
47. Clark AR. Metered Atomisation for Respiratory Drug Delivery [PhD thesis]. Loughborough University of Technology, U.K., 1991.
48. Dunbar CA, Watkins AP, Miller JF. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J Aerosol Med 1997; 10:351-368.
49. Dunbar CA, Watkins AP, Miller JF. A theoretical investigation of the spray issued from a pMDI. Atomization Sprays 1997; 7:417-436.
50. Sirand C, Varlet JP, Hickey AJ. Aerosol-filling equipment for the preparation of pressurized pack pharmaceutical formulations. In: Hickey AJ, ed. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, Inc, 2004:311-343.
51. U.S. Food and Drug Administration. Use of ozone-depleting substances; removal of essential-use designation. U.S. Food and Drug Administration, 2005.
52. Hickey AJ, Concessio NM, Van Oort MM, et al. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol 1994; 18:58-64, 82.
53. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 2007; 96:1282-1301.
54. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci 2007; 96:1302-1319.
55. Louey MD, Van Oort M, Hickey AJ. Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion. J Aerosol Sci 2006; 37:1520-1531.
56. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med 1993; 6:99-110.
57. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5:506-508.
58. Rubin LD. Intal (Cromolyn Sodium) A Monograph. 1st ed. Bedford, MA: Fisons Corporation, 1973.
59. Marple VA. Simulation of respirable penetration characteristics by inertial impaction. J Aerosol Sci 1978; 9:125-134.
60. Vaughan NP. The Andersen impactor: calibration, wall losses and numerical simulation. J Aerosol Sci 1989; 20:67-90.
61. Berglund RN, Liu BYH. Generation of monodisperse aerosol standards. Environ Sci Technol 1973; 7:147-152.
62. Byron PR, Hickey AJ. Spinning-disk generation and drying of monodisperse solid aerosols with output concentrations sufficient for single-breath inhalation studies. J Pharm Sci 1987; 76:60-64.
63. Vervaet C, Byron PR. Polystyrene microsphere spray standards based on CFC-free inhaler technology. J Aerosol Med 2000; 13:105-115.
64. Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers Monograph. USP 29-NF 24 The United States Pharmacopoeia and The National Formulary: The Official Compendia of Standards. Rockville, MD: The United States Pharmacopeial Convention, Inc, 2006:2617-2636.
65. Kamiya A, Sakagami M, Hindle M, et al. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and next generation pharmaceutical impactors and their USP methods. J Pharm Sci 2004; 93:1828-1837.
66. Marple VA, Olson BA, Santhanakrishnan K, et al. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med 2004; 17:335-343.
67. Leung K, Louca E, Gray M, et al. Use of the next generation pharmaceutical impactor for particle size distribution measurements of live viral aerosol vaccines. J Aerosol Med 2005; 18:414-426.
68. Myrdal PB, Mogalian E, Mitchell J, et al. Application of heated inlet extensions to the TSI 3306/3321 system: comparison with the Andersen cascade impactor and next generation impactor. J Aerosol Med 2006; 19:543-554.
69. Berg E, Svensson JO, Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med 2007; 20:97-104.
70. Mitchell JP, Nagel MW, Wiersema KJ, et al. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer. AAPS PharmSciTech 2003; 4:E54.
71. Guo C, Gillespie SR, Kauffman J, et al. Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor. J Pharm Sci 2007; 97(8):3321-3334.
72. Mathias NR, Yamashita F, Lee VHL. Respiratory epithelial cell culture models for evaluation of ion and drug transport. Adv Drug Deliv Rev 1996; 22:215-249.
73. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001; 6:367-375.
74. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med 2005; 18:137-182.
75. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 58:1030-1060.
76. Foster KA, Oster CG, Mayer MM, et al. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998; 243:359-366.
77. Bruck A, Abu-Dahab R, Borchard G, et al. Lectin-functionalized liposomes for pulmonary drug delivery: interaction with human alveolar epithelial cells. J Drug Target 2001; 9:241.
78. Ehrhardt C, Fiegel J, Fuchs S, et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J Aerosol Med 2002; 15:131-139.
79. Hermanns MI, Unger RE, Kehe K, et al. Lung epithelial cell lines in coculture with human microvascular endothelial cells: development of an alveolo-capillary barrier in vitro. Lab Invest 2004; 84:736-752.
80. Foster KA, Avery ML, Yazdanian M, et al. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 2000; 208:1-11.
81. Florea BI, van der Sandt ICJ, Schrier SM, et al. Evidence of p-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br J Pharm 2001; 134:1555-1563.
82. Borchard G, Cassara ML, Roemele PE, et al. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci 2002; 91:1561-1567.
83. Florea BI, Cassara ML, Junginger HE, et al. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003; 87:131-138.
84. Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 2005; 60:193-205.
85. Grainger CI, Greenwell LL, Lockley DJ, et al. Culture of Calu-3 Cells at the air-water interface provides a representative model of the airway epithelial barrier. Pharm Res 2006; 23:1482-1490.
86. Ehrhardt C, Kneuer C, Bies C, et al. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther 2005; 18:165-170.
87. Ehrhardt C, Kneuer C, Laue M, et al. 16HBE14o-human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolin-1. Pharm Res 2003; 20:545-551.
88. Manford F, Tronde A, Jeppsson AB, et al. Drug permeability in 16HBE14o-airway cell layers correlates with absorption from the isolated perfused rat lung. Eur J Pharm Sci 2005; 26:414-420.
89. Robinson PC, Voelker DR, Mason RJ. Isolation and culture of human alveolar type-II epithelial cells. Characterization of their phospholipid secretion. Am Rev Respir Dis 1984; 130:1156-1160.
90. Elbert KJ, Shafer UF, Shafers HJ, et al. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm Res 1999; 16:601-608.
91. Fuchs S, Hollins AJ, Laue M, et al. Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res 2003; 311:31-45.
92. Bur M, Huwer H, Lehr CM, et al. Assessment of transport rates of proteins and peptides across primary human alveolar epithelial cell monolayers. Eur J Pharm Sci 2006; 28:196-203.
93. Lin HC, Li H, Cho HJ, et al. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sci 2007; 96:341-350.
94. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol 2005; 32:281-289.
95. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products-Chemistry, Manufacturing, and Controls Documenta tion. Washington, D.C.: U.S. FDA, CDR, 2002:45.
96. U.S. Food and Drug Administration. Draft Guidance for Industry-Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation. Washington, D.C.: FDA, 1998.
97. European Pharmacopeia. Preparations for Inhalation. European Pharmacopeia, 2001.
98. Evans R. Determination of drug particle size and morphology using optical microscopy. Pharm Technol 1993; 17:146-152.
99. Milosovich SM. Particle-size determination via cascade impaction. Pharm Technol 1992; 16:82-86.
100. Atkins PJ. Aerodynamic particle-size testing-impinger methods. Pharm Technol 1992; 16:26-32.
101. Jager PD, DeStefano GA, McNamara DP. Particle-size measurement using right-angle light scattering. Pharm Technol 1993; 17:102-120.
102. Ranucci JA, Chen F-C. Phase Doppler anemometry: a technique for determining aerosol plume-particle size and velocity. Pharm Technol 1993; 17:62-74.
103. Ranucci J. Dynamic plume-particle size analysis using laser diffraction. Pharm Technol 1992; 16:109-114.
104. Niven RW. Aerodynamic particle size testing using a time-of-flight aerosol beam spectrom eter. Pharm Technol 1993; 72-78.
105. Gorman WG, Carroll FA. Aerosol particle-size determination using laser holography. Pharm Technol 1993; 17:34-37.
106. Hickey AJ, Evans RM. Aerosol generation from propellant-driven metered dose inhalers. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker, Inc., 1996:417-439.
107. Dunbar CA, Hickey AJ. Selected parameters affecting characterization of nebulized aqueous solutions by inertial impaction and comparison with phase-Doppler analysis. Eur J Pharm Biopharm 1999; 48:171-177.
108. Leong BKJ, ed. Inhalation Toxicology and Technology. Ann Arbor: Ann Arbor Science, 1981.
109. Concessio NM, Oort MMV, Knowles M, et al. Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res 1999; 16:828-834.
110. Newman S, Wilding IR, Hirst P. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000; 208:49-60.
111. Meyer T, Brand P, Ehlich H, et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med Deposition Clear Eff Lung 2004; 17:43-49.
112. Bondesson E, Asking L, Borgstrom L, et al. In vitro and in vivo aspects of quantifying intrapulmonary deposition of a dry powder radioaerosol. Int J Pharm 2002; 232:149-156.
113. Sebti T, Pilcer G, Van Gansbeke B, et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm 2006; 64:26-32.
114. Eberl S, Chan HK, Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J Aerosol Med Deposition Clear Eff Lung 2006; 19:8-20.
115. Dolovich M. Lung dose, distribution, and clinical response to therapeutic aerosols. Aerosol Sci Technol 1993; 18:230-240.
116. Vidgren M, Arppe J, Vidgren P, et al. Pulmonary deposition and clinical response of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose powder inhaler. Pharm Res 1994; 11:1320-1324.
117. Vidgren M, Waldrep JC, Arppe J, et al. Study of 99mTechnetium-labeled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm 1995; 115:209-216.
118. Vidgren MT, Karkkainen A, Paronen P, et al. Respiratory tract deposition of 99mTc-labelled drug particles administered via a dry powder inhaler. Int J Pharm 1987; 39:101-105.
119. Vidgren M, Arppe J, Vidgren P, et al. Pulmonary deposition of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose powder inhaler. STP Pharm Sci 1994; 4:29-32.
120. Pitcairn GR, Hooper G, Luria X, et al. A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler. Adv Drug Deliv Rev 1997; 26:59-67.
121. Pitcairn GR, Lim J, Hollingworth A, et al. Scintigraphic assessment of drug delivery from the ultrahaler dry powder inhaler. J Aerosol Med 1997; 10:295-306.
122. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000; 16:178-183.
123. Newman SP, Pitcairn GR, Hirst PH, et al. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003; 55:851-867.
124. Kaliner MA, Barnes PJ, Persson CGA. Asthma, Its Pathology and Treatment. New York: Marcel Dekker, 1991.
125. Adjei A, Garren J. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 1990; 7:565-569.
126. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35:235-247.
127. White S, Bennett DB, Cheu S, et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005; 7:896-906.
128. NDA 21-868/Exubera US Package Insert. New York, NY: Pfizer Labs, 2006:1-24.
129. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7:49-75.
130. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6:67-74.